Science for cure
Personalised cancer therapy
Providing hope for cancer patients: Our vision for a better future
Imagine a world where cancer patients who lack effective treatment options can be cured. With our innovative cell therapy product, currently in clinical trial, we are bringing this vision closer to reality. Our unique approach trains the patient’s own immune cells to target and eliminate cancer cells, providing a tailor-made treatment for each patient.
The story of Neogap
Neogap Therapeutics is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology.
Discover Neogap's innovative pTTL cell therapy and patented technology
Our pTTL cell therapy product, which targets neoantigens, is just one example of our novel technology at Neogap. Manufactured using our proprietary PIOR® and patented EpiTCer® technologies, pTTL consists of T cells targeting neoantigens using immune cells from cancer patients as starting material.
The growing colorectal cancer therapeutics market
Neogap is dedicated to advancing the field of personalised immunotherapy to combat cancer, starting with our focus on colorectal cancer. Our experienced team of professionals from academia and the pharmaceutical industry is committed to developing innovative solutions that are at the forefront of cancer research. Our pTTL cell therapy product is a testament to this dedication.
We also believe in the power of collaboration and are open to partnering with organisations that share our vision for advancing the field of personalised immunotherapy for cancer treatment.
Latest news from Neogap
Neogap receives approval to administer full dose in clinical trial – streamlining development of its personalised cell therapy
Neogap Therapeutics AB, a Swedish clinical-stage biotechnology company developing personalised immunotherapy for cancer treatment, has received approval from the Swedish Medical Products Agency to administer the full dose to all patients in its ongoing phase I/II clinical trial. The decision introduces a more flexible study design and contributes to a faster and more efficient development of the company’s cell therapy.
Neogap Therapeutics selected for EIC Soft-landing Programme in Boston
Neogap Therapeutics, a Swedish biotechnology company developing personalised immunotherapy for cancer treatment, has been selected to participate in the EIC Soft-landing Programme for Healthcare and Life Sciences in Boston, USA. The programme, organised by the European Innovation Council (EIC), aims to support deep tech companies with research-driven technologies and international expansion potential.
Neogap Therapeutics selected for the Innovate Nordics 2025 Acceleration Program
Neogap Therapeutics, a Swedish biotechnology company developing personalised immunotherapy for cancer treatment, is pleased to announce that it has been selected for the prestigious Innovate Nordics 2025 Acceleration Program, organised by the Swedish-American Chamber of Commerce in New York (SACCNY) in partnership with EY.